Adherus™ Dural Sealant in Spinal Procedures

• ClinicalTrials.gov Identifier: NCT04498026
• Recruitment Status: Enrolling by invitation
• First Posted: August 4, 2020
• Last Update Posted: January 17, 2023
• Sponsor: Stryker Craniomaxillofacial
• Collaborator: Laboratory Corporation of America
• Information provided by (Responsible Party): Stryker Craniomaxillofacial

Study Description

Brief Summary:

The purpose of this study is to test an experimental device, the Adherus AutoSpray and Adherus AutoSpray ET Dural Sealant, in spinal surgical procedures.

This study is being done to compare Adherus AutoSpray and Adherus AutoSpray ET Dural Sealant to DuraSeal Exact Spinal Sealant, which has already received Federal Food and Drug Administration (FDA) approval in spinal procedures.

Condition or disease	Intervention/treatment	Phase
Spinal Duraplasty	Device: Adherus Dural Sealant System; Device: DuraSeal Exact Dural Sealant System	Phase 3

Detailed Description:

This is a prospective, randomized, controlled, single-blind, multicenter, pivotal trial that will evaluate the safety and effectiveness of Adherus Dural Sealant when used in conjunction with standard methods of dural repair in spinal procedures. This trial uses the commercially available DuraSeal Exact as an active control. The trial is designed to demonstrate non-inferiority of Adherus Dural Sealant to DuraSeal Exact.

Subjects who are undergoing spinal surgery, consent to participate in this trial and experience a durotomy will be considered for study enrollment. Following a two-tiered inclusion/exclusion consideration, subjects will be randomized intraoperatively using a 1:1 randomization ratio. Up to 114 subjects will be randomized to treatment with either Adherus Dural Sealant or DuraSeal Exact with at least 50% of subjects undergoing procedures at lumbar or lumbosacral levels. Up to 30 investigational sites within the United States will participate in this trial.

A primary composite endpoint evaluating safety and effectiveness will be measured within a 90-day required follow-up period post-procedure. Subjects will be followed at discharge or between postoperative days (POD) 1-4 from the index procedure (whichever occurs first) and at 30 days and 90 days post-index procedure.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 114 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: A Pivotal Clinical Trial Evaluating the Safety and Effectiveness of Adherus™ AutoSpray and Adherus™ AutoSpray ET Dural Sealant When Used as a Dural Sealant in Spinal Procedures
• Actual Study Start Date: November 19, 2020
• Estimated Primary Completion Date: July 2023
• Estimated Study Completion Date: July 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Adherus Dural Sealant System; Device: Adherus Dural Sealant, In situ polymerizing sealant	Device: Adherus Dural Sealant System; Adherus Dural Sealant, In situ polymerizing sealant
Active Comparator: DuraSeal Exact Dural Sealant System; Device: DuraSeal Exact (P080013b)	Device: DuraSeal Exact Dural Sealant System; DuraSeal Exact (P080013b)

Outcome Measures

Primary Outcome Measures :

1. The proportion of treated subjects who are free from the following incidences: [ Time Frame: 90 Days ]
   • CSF leak or pseudomeningocele diagnosed by physical examination, biochemical assay or imaging study during the 90-day follow-up period following the index procedure

   • Unplanned retreatment of the original surgical site adjudicated by the Clinical Events Committee (CEC) to be device-related, other than CSF leak or pseudomeningocele formation or those related to the subject's pre-existing condition, during the 90-day follow-up period including:

     • treatment for deep infection
     • treatment for meningitis
     • minimally invasive procedures or return to the operating room for neurosurgical complications

Secondary Outcome Measures :

1. Secondary endpoints, which will only be tested for superiority of Adherus over DuraSeal Exact after the primary objective of the study has been met: [ Time Frame: 30 Day, 90 Day ]
   • CSF leak or pseudomeningocele diagnosed by physical examination, biochemical assay or imaging study during the 30-day and 90-day follow-up period following the index procedure

   • Unplanned retreatment of the original surgical site adjudicated by the CEC to be device-related, other than CSF leak or pseudomeningocele formation or those related to the subject's pre-existing condition, during the 30-day and 90-day follow-up period including:

     • treatment for deep infection
     • treatment for meningitis
     • minimally invasive procedures or return to the operating room for neurosurgical complications

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subject is ≥ 18 and ≤ 75 years old.
2. Subject is scheduled for an elective spinal procedure that will require a planned durotomy.
3. Subject requires a procedure involving a Class I/clean wound (uninfected surgical wound in which no inflammation is encountered).
4. Subject is able and willing to provide informed consent and HIPAA authorization.

5. Subject is able and willing to meet all study requirements, including attending all post-index procedure assessment visits and radiological tests.

   Intra-Operative Inclusion Criteria:

6. Subject has durotomy edges that can be re-approximated using the investigator's standard methods of dural repair.

Exclusion Criteria:

1. Subject has clinically significant hydrocephalus or clinical evidence of altered CSF dynamics.
2. Subject has a pre-existing external lumbar CSF drain or internal CSF shunt.
3. Subject has experienced previous CSF leak (secondary to trauma, neoplasm, surgery, or other etiology).
4. Subject is undergoing a Chiari malformation procedure.
5. Subject has undergone a previous spinal procedure in the same anatomical location.
6. Subject has had radiation treatment to the surgical site, or standard fractionated radiation therapy is planned within ten days post indexprocedure.
7. Subject has spinal metallic implants that may cause significant imaging artifact on the MRI evaluation of the spine.
8. Subject has metallic implant(s) that are not MRI compatible, e.g., cochlear implant, neurostimulator, stent, surgical clip, cardiac pacemakers, or other non-MRI compatible implants, or an elective implant of such devices is planned during the course of the study. Note: mercury amalgam dental fillings or similar metallic dental prostheses are not an exclusion criterion.
9. Subject has a known malignancy or another condition with anticipated survival shorter than six months.
10. Subject has undergone chemotherapy treatment, excluding hormonal therapy, within three weeks prior to the planned index procedure, or chemotherapy treatment is planned within two weeks after the index procedure is performed.
11. Subject has been treated with chronic steroid therapy (defined as regular (daily) administration of steroid agent(s) for ≥ 8 weeks) unless discontinued greater than four weeks prior to the planned index procedure. Note: standard acute perioperative steroids are permitted; administration of steroid agents for < 8 weeks duration prior to the planned index procedure is permitted.
12. Subject has received warfarin, heparin, other anticoagulant agents, aspirin or non steroid anti-inflammatory agents on a daily basis and pre-surgical, standard of care drug wash-out did not occur.
13. Subject has a compromised immune system or autoimmune disease or is on chronic immunosuppressant agents at baseline.
14. Subject has a systemic infection or evidence of any infection near planned operative site.
15. Subject has a serum creatinine level > 2.0 mg/dL.
16. Subject has a serum total bilirubin > 2.5 mg/dL at baseline.
17. Subject has uncontrolled diabetes as evidenced by an HbA1c > 7% prior to surgery.
18. Subject has a known allergy to FD&C Blue #1 and/or FD&C Yellow #5 or any of the constituents of the dural sealants.
19. Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.

20. Subject is participating in a clinical trial of another investigational drug or device and has not completed the required follow-up period.

    Intra-Operative Exclusion Criteria:

21. Subject has an incidental finding that meets any pre-operative exclusion criterion listed above.
22. Subject's dural defect cannot be closed with suture and/or duraplasty material.
23. Subject has a gap > 2 mm present between dural edges, or between the edge of dura and duraplasty material, based on visual estimate by surgeon before application of the surgical sealant.
24. Subject had undergone laminoplasty decompression.
25. Subject had undergone a syringomyelia procedure where the shunt is not placed in the subarachnoid position.

Contacts and Locations

Locations

United States, California

City of Hope National Medical Center

Duarte, California, United States, 91010

University of California Davis Health

Sacramento, California, United States, 95817

United States, Florida

Mayo Clinic (FL)

Jacksonville, Florida, United States, 32224

United States, Idaho

Saint Alphonsus

Boise, Idaho, United States, 83704

United States, Illinois

Rush University Medical Center

Chicago, Illinois, United States, 60612

University of Illinois at Chicago

Chicago, Illinois, United States, 60612

United States, Minnesota

Mayo Clinic

Rochester, Minnesota, United States, 55902

United States, North Carolina

Carolina Neurosurgery & Spine Associates

Charlotte, North Carolina, United States, 28204

Duke University

Durham, North Carolina, United States, 27705

United States, Pennsylvania

Thomas Jefferson University

Philadelphia, Pennsylvania, United States, 19107

United States, Texas

Houston Methodist Research Institute

Houston, Texas, United States, 77030

Sponsors and Collaborators

Stryker Craniomaxillofacial

Laboratory Corporation of America

More Information

• Responsible Party: Stryker Craniomaxillofacial
• ClinicalTrials.gov Identifier: NCT04498026
• Other Study ID Numbers: HBMT-US-2019-001
• First Posted: August 4, 2020
• Last Update Posted: January 17, 2023
• Last Verified: January 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Keywords provided by Stryker Craniomaxillofacial:

Adherus Dural Sealant; Adherus AutoSpray Dural Sealant; Dura mater; Durotomy; CSF leak